<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782652</url>
  </required_header>
  <id_info>
    <org_study_id>INOT43</org_study_id>
    <nct_id>NCT00782652</nct_id>
  </id_info>
  <brief_title>The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients</brief_title>
  <official_title>The Effects of Nitric Oxide for Inhalation on Survival or the Need for Dialysis or a Right Ventricular Assistance Device (RVAD) in Right Ventricular Infarction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to better understand the effects of nitric oxide, a gas for&#xD;
      inhalation, on patients with right ventricular infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind, placebo-controlled study that will assess&#xD;
      the feasibility of studying inhaled nitric oxide for the treatment of cardiogenic shock due&#xD;
      to right ventricular infarction, and the dose response of the acute hemodynamic changes&#xD;
      occurring with nitric oxide inhalation in these patients. Patients with evidence of right&#xD;
      ventricular infarction and cardiogenic shock, and have angiographic evidence of impaired&#xD;
      blood flow to the right ventricle, or if right ventricular coronary perfusion is unimpared,&#xD;
      cardiac shock persists, will be eligible for enrollment. Patients will receive standard of&#xD;
      care for their condition, and will also recieve either nitric oxide for inhalation or placebo&#xD;
      for up to 14 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment&#xD;
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival to hospital discharge or Day 30, whichever occurs first without the need for renal replacement therapy or a Right Ventricular Assistance Device (RVAD)</measure>
    <time_frame>hospital discharge or Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival at 1 year after initial hospitalization</measure>
    <time_frame>1 year post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time on vasoconstrictor or inotropic medications</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of intraaortic balloon pump support, if applicable</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time in intensive care unit</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration or need for mechanical ventilation</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in cardiac index by dose</measure>
    <time_frame>baseline, hour 8, days 3 &amp; 7, and at day 30 or discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in right ventricule function and size by dose</measure>
    <time_frame>baseline, hour 8, days 3 &amp; 7 and at day 30 or discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in pulmonary vascular resistance by dose</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in any right-to-left intracardiac shunt flow, as assessed by contrast echocardiography</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurohormonal assessment of prognosis with BNP, NT-pro BNP</measure>
    <time_frame>Baseline, hour 8 and days 3 &amp; 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of mortality</measure>
    <time_frame>treatment duration through 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and types of reported adverse events</measure>
    <time_frame>study duration through day 30 or discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Right Ventricular Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>inhaled nitric oxide at 40 or 80ppm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>inhaled nitrogen at either 40 or 80ppm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled nitric oxide</intervention_name>
    <description>Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>INOmax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitrogen gas</intervention_name>
    <description>Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute inferior mycardial infarction (defined as an episode of chest pain lasting &gt;30&#xD;
             minutes and electrocardiographic evidence of 1 mm or greater ST elevation in inferior&#xD;
             leads) within the past 72 hours.&#xD;
&#xD;
          -  Invasive hemodynamic evidence of hemodynamically-significant RV dysfunction, defined&#xD;
             as the presence of all the following: systemic venous congestion (mean RA pressure &gt;&#xD;
             10mmHg), the ratio of RA/PCW pressure 0.75 or greater, a low cardiac output as&#xD;
             determined by Fick or Thermodilution (TD) technique (cardiac index &lt; 2.5 l/min/m2),&#xD;
             systolic systemic arterial blood pressure of 90mmHg or less or requiring vasopressor&#xD;
             or mechanical support to maintain systolic pressure &gt; 90mmHg. Patients with a PCWP of&#xD;
             14mmHg or less should receive intravascular volume repletion until their PCWP is &gt;&#xD;
             14mmHg.&#xD;
&#xD;
          -  Coronary angiography revealing either an occlusion of the RCA proximal to any RV&#xD;
             marginal branch or evidence of diminished flow to RV marginal branches of the RCA.&#xD;
&#xD;
          -  If patient undergoes coronary revascularization, there must be evidence of&#xD;
             unsuccessful right ventricular reperfusion (lack of restoration of TIMI grade III flow&#xD;
             in the distal RCA and &gt; 1mm RV marginal branches) or evidence of hemodynamically&#xD;
             significant RVI must persist for greater than 1 hour after successful&#xD;
             revascularization.&#xD;
&#xD;
          -  Age 18 years or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PCW 25mmHg or greater or mechanical complications of myocardial infarction requiring&#xD;
             surgical correction.&#xD;
&#xD;
          -  Severe LV systolic dysfunction as determined by the principal investigator.&#xD;
             Unprotected left main coronary stenosis &gt; 50%.&#xD;
&#xD;
          -  Pulmonary infiltrates consistent with pulonary edema on chest X-ray (if chest X-ray is&#xD;
             clinically indicated).&#xD;
&#xD;
          -  Evidence of shock-related end-organ damage, including creatinine 3.0 or greater,&#xD;
             metabolic acidosis (pH 7.1 or less) and not corrected by 100 ml NaHCO3 (1mEq/ml),&#xD;
             disseminated intravascular coagulation, or clinical evidence of diffuse brain injury.&#xD;
&#xD;
          -  Previous history of severe pericardial, congenital, or valvular heart disease.&#xD;
&#xD;
          -  Refractory hemodynamically significant arrhythmia.&#xD;
&#xD;
          -  Presence of pneumonia, adult respiratory distress syndrome, or sepsis.&#xD;
&#xD;
          -  Prior history of pulmonary disease requiring chronic oxygen therapy.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of investigational drugs or device within the 30 days prior to enrollment to the&#xD;
             study.&#xD;
&#xD;
          -  Uncontrolled active bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg, University of Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology Warsaw</name>
      <address>
        <city>Alpejska</city>
        <zip>42</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Department, Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocaridal infarction</keyword>
  <keyword>right ventricular infarction</keyword>
  <keyword>cardiogenic shock</keyword>
  <keyword>RVAD</keyword>
  <keyword>Right ventricular assist device</keyword>
  <keyword>cardiac disease</keyword>
  <keyword>right ventricle</keyword>
  <keyword>cardiac shock</keyword>
  <keyword>heart dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

